Cynthia Wong

Cynthia leads Portfolio Planning and Program Management at Denali and is responsible for Denali’s growing portfolio of 10+ programs in various stages of research and clinical development. Cynthia is the Program Director of Denali’s LRRK2 program. In addition, she is involved in developing and evolving Denali’s project team system and decision making processes to support a project-centric organization, whereby project teams are enabled to make high quality decisions with speed.

Prior to Denali, Cynthia was an Associate Director at Genentech’s Research and Early Development Portfolio Planning and Operations group, culminating a career of 12 years at Genentech. Cynthia managed programs from pre-IND through approval in the inflammation, ophthalmology, infectious disease, and oncology disease areas, including products on the market such as Ocrevus (ocrelizumab), Tecentriz (atezolizumab), and Lucentis (ranibizumab).

Cynthia has a B.A. from the University of California at Berkeley in Mass Communications and East Asian Studies.